Evolution of drug-resistant and virulent small colonies in phenotypically diverse populations of the human fungal pathogen Candida glabrata.

Proceedings. Biological Sciences
Sarah DuxburyIvana Gudelj

Abstract

Antimicrobial resistance frequently carries a fitness cost to a pathogen, measured as a reduction in growth rate compared to the sensitive wild-type, in the absence of antibiotics. Existing empirical evidence points to the following relationship between cost of resistance and virulence. If a resistant pathogen suffers a fitness cost in terms of reduced growth rate it commonly has lower virulence compared to the sensitive wild-type. If this cost is absent so is the reduction in virulence. Here we show, using experimental evolution of drug resistance in the fungal human pathogen Candida glabrata, that reduced growth rate of resistant strains need not result in reduced virulence. Phenotypically heterogeneous populations were evolved in parallel containing highly resistant sub-population small colony variants (SCVs) alongside sensitive sub-populations. Despite their low growth rate in the absence of an antifungal drug, the SCVs did not suffer a marked alteration in virulence compared with the wild-type ancestral strain, or their co-isolated sensitive strains. This contrasts with classical theory that assumes growth rate to positively correlate with virulence. Our work thus highlights the complexity of the relationship between resis...Continue Reading

References

Oct 1, 1982·Parasitology·R M Anderson, R M May
Jan 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R A ProctorR D Arbeit
Jan 22, 1994·Proceedings. Biological Sciences·M A Nowak, R M May
Mar 1, 1994·Trends in Microbiology·B R Levin, J J Bull
Mar 1, 1996·The Quarterly Review of Biology·S A Frank
Nov 10, 2000·Journal of Medical Microbiology·J P BoucharaA Defontaine
Apr 3, 2001·International Journal of Antimicrobial Agents·S H Gillespie
May 5, 2001·International Journal of Antimicrobial Agents·M KolárT Látal
Dec 31, 2002·The Lancet Infectious Diseases·Ted CohenMegan Murray
Oct 15, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Olafur GudlaugssonDaniel Diekema
May 17, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jacobus C de RoodeAndrew F Read
Jun 17, 2005·The Journal of Antimicrobial Chemotherapy·Sophie BrunJean-Philippe Bouchara
Sep 24, 2005·Medical Mycology·Derek PaisleyDavid W Denning
Jan 24, 2006·Infection and Immunity·Costi D SifriChristof von Eiff
Aug 8, 2006·Current Opinion in Microbiology·Dan I Andersson
Jan 24, 2008·Heredity·A Buckling, M A Brockhurst
Apr 4, 2008·Evolution; International Journal of Organic Evolution·Frida Ben-AmiDieter Ebert
Feb 1, 1996·International Journal of Antimicrobial Agents·F C Odds
Oct 17, 2008·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Robert L Perlman
Mar 9, 2010·Nature Reviews. Microbiology·Dan I Andersson, Diarmaid Hughes
Sep 15, 2010·Antimicrobial Agents and Chemotherapy·Alicia J ZimbeckShawn R Lockhart
Feb 8, 2011·American Journal of Respiratory and Critical Care Medicine·Eilidh MowatCraig Winstanley
Feb 16, 2011·Antimicrobial Agents and Chemotherapy·Sélène FerrariDominique Sanglard
Mar 15, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Barbara D AlexanderMichael A Pfaller
Apr 5, 2013·Clinical Microbiology Reviews·Alejandro BeceiroGermán Bou
Jan 9, 2015·Clinical Microbiology Reviews·Omar M El-Halfawy, Miguel A Valvano
Mar 20, 2015·Disease Models & Mechanisms·Sascha BrunkeDominique Ferrandon
Apr 11, 2015·Evolutionary Applications·Alex R HallMartin Ackermann
Dec 8, 2015·Evolutionary Applications·Roderich RoemhildHinrich Schulenburg
Dec 31, 2015·PloS One·Christian RitzDaniel Gerhard
Oct 22, 2016·Scientific Reports·Ludovic EnklerFabrice Jossinet
Mar 16, 2017·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Helen C LeggettStuart A West
Apr 1, 1998·Evolution; International Journal of Organic Evolution·Louise H TaylorAndrew F Read
Oct 1, 1994·Evolution; International Journal of Organic Evolution·J J Bull
Jul 1, 2017·Mycoses·Gabriella F Ferreira, Daniel A Santos

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences
Helen C LeggettStuart A West
© 2021 Meta ULC. All rights reserved